LitAlert ~~ GeneLit.com

    • Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor.
    • Liu J, Adhav R, Miao K, Su SM, Mo L, Chan UI, Zhang X, Xu J, Li J, Shu X, Zeng J, Zhang X, Lyu X, Pardeshi L, Tan K, Sun H, Wong KH, Deng C, Xu X.
    • Nat Commun. 2020 Sep 25;11(1):4875. doi: 10.1038/s41467-020-18637-9.
    • The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    • Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD.
    • Gynecol Oncol. 2020 Sep 24:S0090-8258(20)33911-1. doi: 10.1016/j.ygyno.2020.09.018. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.
    • Rajarajan S, C E A, Jose B, Correa M, Sengupta S, Prabhu JS.
    • Mol Clin Oncol. 2020 Nov;13(5):57. doi: 10.3892/mco.2020.2128. Epub 2020 Sep 1.
    • Homologous recombination deficiency real-time clinical assays, ready or not?
    • Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A.
    • Gynecol Oncol. 2020 Sep 20:S0090-8258(20)33852-X. doi: 10.1016/j.ygyno.2020.08.035. Epub ahead of print.
    • Review
  • LitAlert ~~ GeneLit.com

    • Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition.
    • Milletti G, Strocchio L, Pagliara D, Girardi K, Carta R, Mastronuzzi A, Locatelli F, Nazio F.
    • Cancers (Basel). 2020 Sep 20;12(9):E2684. doi: 10.3390/cancers12092684.
    • Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.
    • Green RF, Kumerow MT, Rodriguez JL, Addie S, Beachy SH, Senier L.
    • Public Health Genomics. 2020 Sep 17:1-12. doi: 10.1159/000510336. Epub ahead of print.

    Original research:

    Proposed outcomes measures for state public health genomic programs.

    • BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
    • Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C.
    • EBioMedicine. 2020 Sep 11;60:102988. doi: 10.1016/j.ebiom.2020.102988. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors.
    • Pasculli B, Barbano R, Fontana A, Biagini T, Di Viesti MP, Rendina M, Valori VM, Morritti M, Bravaccini S, Ravaioli S, Maiello E, Graziano P, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P.
    • Front Oncol. 2020 Aug 12;10:1415. doi: 10.3389/fonc.2020.01415.
    • AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
    • Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM.
    • Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
    • Potential doxorubicin-mediated dual-targeting chemotherapy in FANC/BRCA-deficient tumors via modulation of cellular formaldehyde concentration.
    • Nakamura J.
    • Chem Res Toxicol. 2020 Sep 2. doi: 10.1021/acs.chemrestox.0c00288. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Ultrasensitive colorimetric biosensor for BRCA1 mutation based on multiple signal amplification strategy.
    • Bai Y, Li H, Xu J, Huang Y, Zhang X, Weng J, Li Z, Sun L.
    • Biosens Bioelectron. 2020 Oct 15;166:112424. doi: 10.1016/j.bios.2020.112424. Epub 2020 Jul 11.
    • Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
    • Goncalves A, Mezni E, Bertucci F.
    • Curr Opin Oncol. 2020 Aug 26. doi: 10.1097/CCO.0000000000000680. Epub ahead of print.
    • Review